25 documents

Read All
08:00 , Feb 7, 2011 |  BC Week In Review  |  Clinical News

AS1411: Phase IIb discontinued

Antisoma discontinued an open-label, international Phase IIb trial of AS1411 after early data from about 45 patients showed that the compound was unlikely to show a clear benefit. The company said it will focus on...
Read More
07:00 , Mar 29, 2010 |  BC Week In Review  |  Clinical News

AS1411: Phase IIb started

Antisoma began an open-label, international Phase IIb trial in about 90 AML patients in first relapse or refractory to one prior treatment. The trial will evaluate cytarabine with or without 40 or 80 mg/kg/day AS1411....
Read More
08:00 , Dec 21, 2009 |  BC Week In Review  |  Clinical News

AS1411: Interim Phase II data

Antisoma discontinued development of AS1411 to treat RCC after interim data from an open-label, single-arm U.S. Phase II trial in 35 patients showed the compound's median PFS was inferior to everolimus' median PFS of 4.9...
Read More
01:40 , Dec 17, 2009 |  BC Extra  |  Clinical News

Antisoma discontinues AS1411 for RCC

Antisoma plc (LSE:ASM) discontinued development of AS1411 to treat renal cell carcinoma after interim data from a Phase II trial showed that the compound's median progression-free survival was inferior to everolimus' PFS of 4.9 months...
Read More
07:00 , Oct 19, 2009 |  BC Week In Review  |  Clinical News

AS1411 regulatory update

FDA and the EC granted Orphan Drug designation for Antisoma's AS1411 to treat acute myelogenous leukemia (AML). The anti- nucleolin aptamer is in Phase II testing for the indication. AS1411 already has Orphan designation in...
Read More
07:00 , Jun 8, 2009 |  BC Week In Review  |  Clinical News

AS1411: Additional Phase II data

Data from 59 evaluable patients in the open-label, U.S. Phase II showed that 10 and 40 mg/kg/day IV AS1411 plus cytarabine resulted in response rates of 21% (4/19) and 19% (4/21), respectively, vs. 5% (1/19)...
Read More
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

AS1411: Interim Phase II data

Interim data from 28 evaluable patients in the open-label, U.S. Phase II AS1411-C-201 trial showed that 10 mg/kg/day AS1411 plus cytarabine produced 2 CRS, 1 CR with incomplete platelet recovery (CRp) and 1 cytogenetic response....
Read More
07:00 , Apr 14, 2008 |  BC Week In Review  |  Clinical News

Antisoma, Archemix preclinical data

Data published in Cancer Research showed that a 5 µmol/L dose of AS1411 inhibited breast cancer cell growth while a 4-fold higher dose had no discernible effects on normal breast cells. The anti- nucleolin aptamer...
Read More
07:00 , Apr 14, 2008 |  BioCentury  |  Product Development

Antisoma's MOA support

Antisoma plc has been developing its AS1411 for acute myelogenous leukemia and renal cancer based on its ability to induce apoptosis in cancer cells while sparing healthy cells. Exactly how the aptamer does this has...
Read More
07:00 , Oct 9, 2006 |  BC Week In Review  |  Clinical News

AS1411: Additional Phase I data

Additional data from a Phase I trial in 17 renal and lung cancer patients showed that AS1411 was safe and well tolerated. Of 5 lung cancer patients, 2 had stable disease for >=2 months. Of...
Read More